APO-Landing Page (1200x628) APO-Landing Page (1200x628)

Supporting children with epilepsy with Green Zone Japan

Always Pure Organics are very proud to be supporting the “Midori-no-wa (Green Circle) project for children with intractable epilepsy in Japan” with Green Zone Japan.

Green Zone Japan is a Japanese medical cannabis advocacy group focusing on bringing evidence-based, accurate and up-to-date information on medical cannabis to Japanese medical professionals and the general public.

Since June 2020, we have supported around 30 patients so far and amongst them, 7 patients including 2.5 years old girl (featured) whose seizures were completely eliminated by our THC Free Distillate.  

One of the problems we have in Japan is that, due to being unable to manufacture source material domestically, people rely on imported products; this drives up retail prices, making it extremely difficult for anyone to use high enough dosages to be therapeutically effective on a continual basis.

Therefore, we decided to support providing paediatric patients access to therapeutic level doses of CBD products at an affordable price. We do this with the understanding and consent of the patients’ primary doctors so as not to disturb their treatment regimen and to cause adverse drug interactions.

For more information on the project and the CBD landscape in Japan watch the video here and our previous blog post here.

Always Pure Organics are very proud to be supporting the “Midori-no-wa (Green Circle) project for children with intractable epilepsy in Japan” with Green Zone Japan.

Green Zone Japan is a Japanese medical cannabis advocacy group focusing on bringing evidence-based, accurate and up-to-date information on medical cannabis to Japanese medical professionals and the general public.

Since June 2020, we have supported around 30 patients so far and amongst them, 7 patients including 2.5 years old girl (featured) whose seizures were completely eliminated by our THC Free Distillate.  

One of the problems we have in Japan is that, due to being unable to manufacture source material domestically, people rely on imported products; this drives up retail prices, making it extremely difficult for anyone to use high enough dosages to be therapeutically effective on a continual basis.

Therefore, we decided to support providing paediatric patients access to therapeutic level doses of CBD products at an affordable price. We do this with the understanding and consent of the patients’ primary doctors so as not to disturb their treatment regimen and to cause adverse drug interactions.

For more information on the project and the CBD landscape in Japan watch the video here and our previous blog post here.
APO-Landing Page (1200x628) APO-Landing Page (1200x628) APO-Landing Page (1200x628)
Andrew Megahy1

Andrew Megahy

Lead Scientific Officer Linkedin